Braze (NASDAQ:BRZE) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent. The company reported quarterly sales of $86.10 million which beat the analyst consensus estimate of $81.10 million by 6.17 percent.
Immunome To Present At Cantor Healthcare Conference Wednesday, Sept. 29 At 8:40 a.m. EDT
Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that Purnanand Sarma, Ph.D.,